Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Sapna Oberoi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Sarcoma, Rhabdomyosarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
In the United States, approximately 850–900 children and adolescents each year are diagnosed with soft tissue sarcomas (STS). STS are divided into rhabdomyosarcoma (RMS) and non‐rhabdomyosarcoma STS (NRSTS). RMS and NRSTS are risk stratified into low‐, intermediate‐, and high‐risk categories, with 5‐year survival rates of approximately 90%, 50%–70%, and 20%, respectively. Recent key achievements from the Children's Oncology Group (COG) STS Committee include the identification of new molecular prognostic factors for RMS, development and validation of a novel risk stratification system for NRSTS, successful completion of a collaborative NRSTS clinical trial with adult oncology consortia, and collaborative development of the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). Current COG trials for RMS are prospectively evaluating a new risk stratification system that incorporates molecular findings, de‐intensification of therapy for a very low‐risk subgroup, and augmented therapy approaches for intermediate‐ and high‐risk RMS. Trials for NRSTS exploring novel targets and local control modalities are in development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
- Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
- Department of Pediatrics, Stanford University, Stanford, California, USA.
- Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA.
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
ORCID-Profile: Sapna Oberoi, Erin R Rudzinski
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Oberoi, S., Crane, J. N., Haduong, J. H., Rudzinski, E. R., Wolden, S. L., Dasgupta, R., Linardic, C. M., Weiss, A. R., Venkatramani, R., & the Children's Oncology Group Soft Tissue Sarcoma Committee (2023). Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30556
Vancouver
Oberoi S, Crane JN, Haduong JH, Rudzinski ER, Wolden SL, Dasgupta R, et al. Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30556
BibTeX
@article{Oberoi2023,
author = {Oberoi, Sapna and Crane, Jacquelyn N and Haduong, Josephine H and Rudzinski, Erin R and Wolden, Suzanne L and Dasgupta, Roshni and Linardic, Corinne M and Weiss, Aaron R and Venkatramani, Rajkumar and the Children's Oncology Group Soft Tissue Sarcoma Committee, the Children's Oncology Group Soft Tissue Sarcoma Committee},
title = {Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30556}
}
EUVIMED